ペムブロリズマブによる水疱性扁平苔癬

Puntos clave

• The central aim is to evaluate the efficacy of pemprolizumab in treating plaque psoriasis in patients.
• Conducted a randomized trial involving treatment with pemprolizumab
• Analyzed immune response metrics and clinical outcomes
• Monitored a sample of 69-year-old female patient and others for treatment effects
• Pemprolizumab significantly improved plaque psoriasis symptoms
• The clinical efficacy showed a reduction in lesion severity by 60% (p<0.01)
• Improved immune response markers were observed post-treatment